Associated Centers & Laboratories
The CTBH is a P30 "Center of Excellence" funded by NIDA and directed by Lisa Marsch, PhD. The CTBH is located off campus, one mile from Dartmouth College campus and a quarter mile from Dartmouth Hitchcock Medical Center. The CTBH affiliates are based at institutions across the country. Comprised of an interdisciplinary team of leaders in behavioral science and technology, the overarching aim of the CTBH is to integrate expertise across multiple disciplines and provide an infrastructure to enhance the quality, pace of achievement and impact of innovative scientific research and development activities that systematically combine science-based behavior change interventions with state-of-the-science technologies to create, empirically test and disseminate technology-based interventions targeting substance use disorders and related issues.
CTBH is comprised of a wide array of researchers, technologists and clinicians with interest in developing, studying, and using technology-based tools for the assessment, treatment and prevention of substance use and related disorders.
The CTBH team shares a common goal of seeking to harness existing and emerging technologies to effectively develop and deliver evidence-based interventions for substance use and co-occurring disorders. CTBH faculty is organized into two primary cores: Scientific Core and Dissemination & Implementation Core. Core activities focus on identifying and studying state-of-the-art issues related to each of these core topics as they relate to technology-delivered therapeutic tools targeting behavioral health.
The Norris Cotton Cancer Center is an NCI-funded comprehensive cancer center, one of 40 such centers in the United States. NCCC is home to some 250 active research projects, led by its 135 cancer research scientists, and supported by 68 million in grants each year from federal and other sources. Research is divided into 6 programs based on the research theme. The program applicable to our T32 is the Cancer Control Research Program (CCRP), which is located in the Dartmouth-Hitchcock Medical Center. CCRP investigators study cancer risk behaviors (tobacco, alcohol, unhealthy eating) and the delivery of cancer care. Dr. James Sargent, M.D. shares program leadership with Anna Tosteson of TDI, and directs the Behavioral Science portfolio of the CCRP. The primary focus of Dr. Sargent's research is tobacco control, which increasingly is studying how FDA tobacco policy may impact tobacco use in adolescents, young adults and persons with severe mental illness. The NCCC/CCRP includes an array of supportive core resources, including Biostatistical Shared Services, a Geospatial Resource (important in our studies of proximity to point of sale marketing), a Media Resource (that aids in identifying and content coding movies and marketing for substance use), and a Registry Resource (which is developing a registry of tobacco users).
Meghan Meyer, PhD, Director
Two-thirds of human socializing centers on exchanging information about people: their behaviors, thoughts, and traits. Yet, how we track the social information swarming our everyday lives remains largely unknown. Our research integrates social and cognitive neuroscience to understand what drives our tendency, ability, and need to think about the social world around us. We aim to answer questions such as: How do we juggle multiple social cognitive demands on the fly? How do we learn and consolidate information about the people and groups with whom we interact? Why do the negative and positive experiences with people from our past seem to linger with us, either by haunting us with pain or consuming us with nostalgia? Our three primary areas of research are Social Working Memory, Social Cognition and the Default Network, and Social Cognition and Affect.
David J. Bucci, PhD, Department of Psychological & Brain Sciences, Dartmouth College.
Our laboratory studies the behavioral and neurobiological factors that regulate learning and memory. We combine classical conditioning procedures with biochemical, chemogenetic, pharmacological and neuroanatomical techniques to study topics such as functional interactions between cortical-hippocampal systems, mechanisms underlying attention and learning, and the development of learning and memory processes. One goal of this research is to further our understanding of the basic mechanisms of information processing in the brain. A second goal is to relate these findings to the biological basis of cognitive dysfunction and mental illness in humans.
We are in the Department of Psychological and Brain Sciences at Dartmouth College. Our lab's research centers on understanding how the brain generates reward, motivation, actions, and habits. To do this, we incorporate a range of techniques for monitoring and studying the activity of brain cells. We also study how disorders of reward and action arise, like addictions, Parkinson's disease, and obsessive-compulsive spectrum disorders.
The ARP, administratively housed in the Department of Psychiatry, comprises four investigators whose research spans behavioral and neurobiological mechanism studies of addiction and mental illness processes to clinical trials testing behavioral and pharmacological interventions. Dr. Green, in collaboration with Dr. Mary Brunette has developed a network of five outpatient clinical sites (all affiliated with Dartmouth) that work together as the Psychopharmacology Research Group (PRG) to implement clinical trials in schizophrenia and SUDs. The PRG designs and coordinates NIH and industry sponsored studies at Dartmouth and through a network of clinical sites in New Hampshire and Vermont. On-going animal research is closely linked to the work of the Neuroscience Center at Dartmouth. These translational studies investigate animal models of schizophrenia, alcoholism, and cannabis dependence to further probe the basis of these disorders, and to test potential therapeutic agents and techniques. Ongoing human neuroimaging studies use fMRI techniques to elucidate structural and functional deficits in patients with CODs.
Also, within the ARP is the Mood Disorders Research Clinic (MDRC), directed by Dr. Paul Holtzheimer. The MDRC focuses on the neurobiology and treatment of mood disorders, including trials of psychotherapy and novel antidepressant therapies including transcranial magnetic stimulation and deep brain stimulation.